CIK 0001609809 · Non-accelerated filer<br>Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 274326290
- Phone
- 617 945 9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230
- in 4 filings, $2K under 10b5-1 plans
Net −$2,230. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-15 | Shaff Eric D. CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −7,813 | 62,500 | ||
| 2025-02-15 | Shaff Eric D. CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −26,563 | 79,687 | ||
| 2025-02-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise 10b5-1 | +2,657 | 137,849 | ||
| 2025-02-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise 10b5-1 | +8,907 | 146,756 | ||
| 2025-02-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise · Restricted Stock Units 10b5-1 | −2,657 | 21,250 | ||
| 2025-02-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise · Restricted Stock Units 10b5-1 | −8,907 | 26,718 | ||
| 2025-02-15 | von Moltke Lisa See Remarks | Option exercise 10b5-1 | +2,969 | 35,384 | ||
| 2025-02-15 | von Moltke Lisa See Remarks | Option exercise 10b5-1 | +8,907 | 44,291 | ||
| 2025-02-15 | von Moltke Lisa See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −2,969 | 23,750 | ||
| 2025-02-15 | von Moltke Lisa See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −8,907 | 26,718 | ||
| 2025-02-07 | Thorell Marella See Remarks | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2025-02-07 | Henn Matthew R. See Remarks | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2025-02-07 | Young Teresa L. See Remarks | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2025-02-07 | Shaff Eric D. CEO and President | Grant or award · Stock Option (Right to Buy) | +1,950,000 | 1,950,000 | ||
| 2025-02-07 | von Moltke Lisa See Remarks | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2025-02-07 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2025-02-04 | Woerle Hans-Juergen Director | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2024-11-18 | DesRosier Thomas Chief Legal Officer and EVP | Sale 10b5-1 | −878 | $0.54 | $475 | 135,192 |
| 2024-11-18 | von Moltke Lisa See Remarks | Sale 10b5-1 | −977 | $0.54 | $528 | 32,415 |
| 2024-11-18 | Young Teresa L. See Remarks | Sale 10b5-1 | −735 | $0.54 | $398 | 90,404 |
Page 9 of 13 · 254 trades